The long-term cardiac monitoring for detection of atrial fibrillation (AF) after cryptogenic stroke is a pilot study involving five centers in Canada and the US. The primary endpoint of the study is to determine the incidence of AF at one year from Sleuth AT implantation in patients who have had cryptogenic stroke.
According to Transoma, Sleuth AT allows physicians to program the capture of high-quality ECG strips at frequent intervals, providing a new level of insight into complex arrhythmias which are often asymptomatic and frequently changing.
These captured ECG strips are automatically transferred to a 24/7 monitoring center, staffed by certified cardiac technicians, who classify and notify physicians of the presence of a wide variety of cardiac arrhythmias such as ventricular tachycardia, bradycardia, supraventricular tachycardia and atrial fibrillation, the company said.
Brian Brockway, founder and CEO of Transoma Medical, said: “Having this study underway is a milestone because AF could be the cause of a large number of cryptogenic strokes. AF is a common cardiac arrhythmia that is challenging to manage. However, we believe Sleuth AT is a unique and superior method for monitoring AF and the effects of current and future therapies.”